ID   EM-2
AC   CVCL_1196
SY   EM2
DR   BTO; BTO:0005904
DR   CLO; CLO_0002922
DR   EFO; EFO_0002176
DR   CLDB; cl1164
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03472895
DR   CCLE; EM2_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR   Cell_Model_Passport; SIDM01047
DR   ChEMBL-Cells; CHEMBL3308889
DR   ChEMBL-Targets; CHEMBL2366281
DR   Cosmic; 787491
DR   Cosmic; 906855
DR   Cosmic; 994175
DR   Cosmic; 1026572
DR   Cosmic; 1078728
DR   Cosmic; 1498416
DR   Cosmic-CLP; 906855
DR   DSMZ; ACC-135
DR   GDSC; 906855
DR   GEO; GSM887004
DR   GEO; GSM888073
DR   GEO; GSM1374474
DR   GEO; GSM1669762
DR   IARC_TP53; 340
DR   IARC_TP53; 21326
DR   IGRhCellID; EM2
DR   LINCS_LDP; LCL-1112
DR   Wikidata; Q54832264
RX   CelloPub=CLPUB00038;
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=3332852;
RX   PubMed=3856862;
RX   PubMed=10637496;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=27397505;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Doubling time: ~35-40 hours (DSMZ).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Homozygous for TP53 p.Arg248Gln (c.743G>A) (IARC_TP53 from Cosmic-CLP).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Derived from sampling site: Bone marrow.
ST   Source(s): Cosmic-CLP; DSMZ; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 9,12
ST   D16S539: 11,12
ST   D18S51: 13,15
ST   D21S11: 30
ST   D3S1358: 14,16
ST   D5S818: 8,12
ST   D7S820: 10
ST   D8S1179: 14
ST   FGA: 21,22
ST   Penta D: 13,14
ST   Penta E: 7,16
ST   TH01: 9.3
ST   TPOX: 8,12
ST   vWA: 14,17
DI   NCIt; C7320; Childhood chronic myelogenous leukemia, BCR-ABL1 positive
OX   NCBI_TaxID=9606; ! Homo sapiens
OI   CVCL_2033 ! EM-3
SX   Female
AG   5Y
CA   Cancer cell line
//
RX   CelloPub=CLPUB00038;
RA   Keating A., Martin P.J., Bernstein I.D., Papayannopoulou T.,
RA   Raskind W., Singer J.W.;
RT   "EM-2 and EM-3: two new Ph'+ myeloid cell lines.";
RL   (In) Normal and neoplastic hematopoiesis, UCLA symposia on molecular and cellular biology, New Series Vol. 9; Golde D.W., Marks P.M. (eds.); pp.513-520; Alan R. Liss; New York (1983).
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=3332852; DOI=10.1016/S0950-3536(87)80037-9;
RA   Keating A.;
RT   "Ph positive CML cell lines.";
RL   Baillieres Clin. Haematol. 1:1021-1029(1987).
//
RX   PubMed=3856862; DOI=10.1073/pnas.82.6.1810;
RA   Konopka J.B., Watanabe S.M., Singer J.W., Collins S.J., Witte O.N.;
RT   "Cell lines and clinical isolates derived from Ph1-positive chronic
RT   myelogenous leukemia patients express c-abl proteins with a common
RT   structural alteration.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:1810-1814(1985).
//
RX   PubMed=10637496; DOI=10.1038/sj.leu.2401604;
RA   Drexler H.G., Fombonne S., Matsuo Y., Hu Z.-B., Hamaguchi H.,
RA   Uphoff C.C.;
RT   "p53 alterations in human leukemia-lymphoma cell lines: in
RT   vitro artifact or prerequisite for cell immortalization?";
RL   Leukemia 14:198-206(2000).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//